FDA staff cautious on AstraZeneca, Bristol diabetes drug
LONDON (Reuters) - U.S. Food and Drug Administration staff said on Tuesday they were wary about the benefits versus the risks of AstraZeneca and Bristol-Myers Squibb's new diabetes drug dapagliflozin.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: AstraZeneca | Dapagliflozin | Diabetes | Endocrinology | Food and Drug Administration (FDA) | Forxiga | Health